Covered recipient · General Payments record
JIBRAN E ATWI
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$946.82
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $887.82 | 49 |
| Education | $59.00 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $372.88 | 18 |
| Amgen Inc. | $82.61 | 3 |
| Kowa Pharmaceuticals America, Inc. | $62.27 | 3 |
| Regeneron Healthcare Solutions, Inc. | $50.68 | 2 |
| Ionis Pharmaceuticals, Inc. | $45.61 | 2 |
| Pharming Healthcare, Inc. | $45.16 | 2 |
| Organon LLC | $37.87 | 6 |
| GlaxoSmithKline, LLC. | $37.60 | 2 |
| Merck Sharp & Dohme LLC | $35.98 | 2 |
| Galderma Laboratories, L.P. | $35.83 | 2 |
| MILLICENT US INC | $29.83 | 2 |
| LEO Pharma Inc. | $26.51 | 1 |
| Phadia US Inc. | $20.86 | 1 |
| AstraZeneca Pharmaceuticals LP | $19.08 | 1 |
| SANOFI PASTEUR INC. | $14.09 | 1 |
| Supernus Pharmaceuticals, Inc. | $13.64 | 1 |
| PFIZER INC. | $12.66 | 1 |
| Corium, LLC | $3.66 | 1 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JIBRAN E ATWI
NPI 1154322923 · CMS profile ID 142445
Allopathic & Osteopathic Physicians / Allergy & Immunology
LAFAYETTE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $946.82 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $12.20 | 01/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233640153 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,678,691.77 | 331 |
| PY2024 | Recipient | $1,002.46 | 7 |
| PY2024 | Principal investigator | $3,616,597.58 | 183 |
| PY2023 | Recipient | $1,120.25 | 4 |
| PY2023 | Principal investigator | $2,225,098.34 | 177 |
| PY2022 | Principal investigator | $1,051,985.35 | 225 |
| PY2021 | Principal investigator | $102,186.90 | 23 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
331 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $849.75 | 12/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension | No dispute reported | 06/30/2026 | 1202535093 |
| Principal investigator 1 | ABBVIE INC. | $695.25 | 12/31/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age with Functional Constipation (FC). | No dispute reported | 06/30/2026 | 1202535095 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $43,881.48 | 12/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Lafayette | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease | No dispute reported | 06/30/2026 | 1232934498 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,608.54 | 12/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718386 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 12/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) | No dispute reported | 06/30/2026 | 1252946550 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273766 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273768 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273770 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273772 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273774 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273778 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279441 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279443 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279445 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279447 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279449 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279451 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279453 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280665 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280667 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280669 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280671 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280673 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280675 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280677 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280679 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280681 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280683 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280685 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280687 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280689 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280691 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280693 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280823 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280825 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280827 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280829 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280831 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280833 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280837 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280839 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280841 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280843 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280845 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280847 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280849 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280851 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280853 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280855 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280857 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280859 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280861 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280863 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280865 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280867 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280869 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280871 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280873 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280875 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280935 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280937 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280939 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280941 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280943 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280945 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280947 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280949 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280951 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280953 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280955 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280957 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280959 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280961 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280963 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280965 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280967 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280969 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280971 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280973 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280975 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280977 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280979 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280981 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280983 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280985 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280987 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280989 |
| Principal investigator 1 | ModernaTX, Inc. | $626.00 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955419 |
| Principal investigator 1 | ModernaTX, Inc. | $644.47 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955437 |
| Principal investigator 1 | ModernaTX, Inc. | $1,357.00 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955513 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955555 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955559 |
| Principal investigator 1 | ABBVIE INC. | $7,750.00 | 12/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202530580 |
| Principal investigator 1 | ABBVIE INC. | $354.00 | 12/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202530592 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,666.00 | 12/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130802 |
| Principal investigator 1 | Novavax Inc | $250,556.40 | 12/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242919974 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $598.50 | 12/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046672 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,572.80 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130786 |
| Principal investigator 1 | Novavax Inc | $14,500.00 | 12/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242918770 |
| Principal investigator 1 | Novavax Inc | $1,700.00 | 12/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242919489 |
| Principal investigator 1 | Novavax Inc | $105,809.40 | 12/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242920853 |
| Principal investigator 1 | ModernaTX, Inc. | $3,724.00 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955481 |
| Principal investigator 1 | ModernaTX, Inc. | $3,769.60 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955517 |
| Principal investigator 1 | ModernaTX, Inc. | $425.00 | 11/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003491 |
| Principal investigator 1 | ModernaTX, Inc. | $1,444.00 | 11/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003503 |
| Principal investigator 1 | ModernaTX, Inc. | $30,000.00 | 11/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) | No dispute reported | 06/30/2026 | 1252946548 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 11/25/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226089867 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $625.00 | 11/25/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226089884 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $575.00 | 11/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192133321 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 11/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130908 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $22,469.00 | 11/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130745 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,010.82 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226089980 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,186.67 | 11/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718228 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,024.00 | 11/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1192133341 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $300.28 | 11/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH LAFAYETTE | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190310849 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 11/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202522379 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 11/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202522429 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 11/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202522493 |
| Principal investigator 1 | Seqirus USA Inc | $2,564.40 | 11/03/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809737 |
| Principal investigator 1 | Seqirus USA Inc | $704.70 | 11/03/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809742 |
| Principal investigator 1 | ModernaTX, Inc. | $5,760.80 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955391 |
| Principal investigator 1 | ModernaTX, Inc. | $37,240.00 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955519 |
| Principal investigator 1 | ModernaTX, Inc. | $44,292.80 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955521 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,075.00 | 10/23/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226114890 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,469.80 | 10/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718128 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $197.12 | 10/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130932 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,800.00 | 10/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130700 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $493.29 | 10/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046674 |
| Principal investigator 1 | Novavax Inc | $1,323.55 | 10/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242921252 |
| Principal investigator 1 | ModernaTX, Inc. | $6,236.81 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955393 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955465 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955505 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $76,859.00 | 09/29/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130696 |
| Principal investigator 1 | Novavax Inc | $4,522.44 | 09/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242920850 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,500.00 | 09/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185550703 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,634.50 | 09/22/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | No dispute reported | 06/30/2026 | 1226130693 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $21,500.00 | 09/19/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc. | BMN 111-210 | No dispute reported | 06/30/2026 | 1248580692 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,641.20 | 09/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046676 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,650.00 | 09/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192133297 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,630.60 | 09/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase one,open label,single dose study to evaluate the pharmacokinetics of inhaled in adolescents with asthma | No dispute reported | 06/30/2026 | 1185550713 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/03/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276820 |
| Principal investigator 1 | Seqirus USA Inc | $177.19 | 09/03/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276840 |
| Principal investigator 1 | Seqirus USA Inc | $789.00 | 09/03/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276850 |
| Principal investigator 1 | Novavax Inc | $761.82 | 08/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242918777 |
| Principal investigator 1 | Genentech, Inc. | $13,962.00 | 08/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211682096 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,000.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554919 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $4,850.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554921 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $12,000.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554923 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $750.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554925 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $1,000.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554927 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $850.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554929 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $1,000.00 | 08/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554931 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,172.00 | 08/18/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130597 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,388.70 | 08/18/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $175.00 | 08/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130599 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,211.50 | 08/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130622 |
| Principal investigator 1 | Novavax Inc | $6,402.35 | 08/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919116 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 07/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185277155 |
| Principal investigator 1 | Seqirus USA Inc | $14,500.00 | 07/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185277157 |
| Principal investigator 1 | Seqirus USA Inc | $27,126.40 | 07/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185277159 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 07/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046694 |
| Principal investigator 1 | ModernaTX, Inc. | $1,180.59 | 07/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955413 |
| Principal investigator 1 | ModernaTX, Inc. | $985.50 | 07/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955487 |
| Principal investigator 1 | ModernaTX, Inc. | $985.50 | 07/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955489 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $700.00 | 07/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046678 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,150.00 | 07/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192133334 |
| Principal investigator 1 | ModernaTX, Inc. | $11,840.00 | 07/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003513 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,300.00 | 07/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130501 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,296.80 | 07/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130541 |
| Principal investigator 1 | ABBVIE INC. | $3,613.00 | 07/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202494659 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,122.00 | 07/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | No dispute reported | 06/30/2026 | 1226130519 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $325.00 | 07/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130526 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,725.00 | 06/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185550715 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,221.17 | 06/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717942 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $515.13 | 06/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718020 |
| Principal investigator 1 | ModernaTX, Inc. | $787.06 | 06/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955417 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,310.00 | 06/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226130409 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 06/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130431 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,856.70 | 06/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130435 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 06/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130440 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,850.00 | 06/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130443 |
| Principal investigator 1 | Novavax Inc | $4,570.92 | 06/13/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919985 |
| Principal investigator 1 | ModernaTX, Inc. | $114,000.00 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003517 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 06/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202490869 |
| Principal investigator 1 | Genentech, Inc. | $1,023.00 | 06/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211682086 |
| Principal investigator 1 | ModernaTX, Inc. | $15,298.25 | 06/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955529 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202490449 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $247.00 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717617 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $617.50 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717799 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130939 |
| Principal investigator 1 | ModernaTX, Inc. | $495.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003509 |
| Principal investigator 1 | ModernaTX, Inc. | $22,925.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003511 |
| Principal investigator 1 | Novavax Inc | $5,015.25 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242920857 |
| Principal investigator 1 | ModernaTX, Inc. | $4,050.00 | 06/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955457 |
| Principal investigator 1 | ModernaTX, Inc. | $135.00 | 06/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955459 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955545 |
| Principal investigator 1 | ModernaTX, Inc. | $561.00 | 06/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955423 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955471 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $9,288.51 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717867 |
| Principal investigator 1 | ModernaTX, Inc. | $744.80 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955429 |
| Principal investigator 1 | ModernaTX, Inc. | $2,802.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955431 |
| Principal investigator 1 | ModernaTX, Inc. | $53,716.80 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955433 |
| Principal investigator 1 | ModernaTX, Inc. | $149,780.80 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955485 |
| Principal investigator 1 | ModernaTX, Inc. | $1,574.12 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955549 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $198.58 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | No dispute reported | 06/30/2026 | 1226130383 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $104,611.00 | 05/26/2025 | Non-covered Recipient Entity Velocity Clinical Research, Lafayette | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease | No dispute reported | 06/30/2026 | 1232934324 |
| Principal investigator 1 | ModernaTX, Inc. | $98,800.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003515 |
| Principal investigator 1 | ModernaTX, Inc. | $334.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003523 |
| Principal investigator 1 | ModernaTX, Inc. | $3,602.62 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252955409 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252955451 |
| Principal investigator 1 | ModernaTX, Inc. | $1,550.00 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252955453 |
| Principal investigator 1 | ModernaTX, Inc. | $780.00 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252955495 |
| Principal investigator 1 | Novavax Inc | $15,867.29 | 05/15/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919982 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $749.32 | 05/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192133316 |
| Principal investigator 1 | ModernaTX, Inc. | $13,399.50 | 05/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | No dispute reported | 06/30/2026 | 1252955449 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 05/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202484361 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202484363 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 05/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202484365 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 05/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202484367 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,537.00 | 05/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130363 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,969.00 | 05/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185550709 |
| Principal investigator 1 | ModernaTX, Inc. | $2,809.61 | 05/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955533 |
| Principal investigator 1 | ModernaTX, Inc. | $3,040.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003497 |
| Principal investigator 1 | ModernaTX, Inc. | $1,670.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003519 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $6,872.82 | 04/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717747 |
| Principal investigator 1 | Novavax Inc | $14,020.55 | 04/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919105 |
| Principal investigator 1 | Novavax Inc | $19,944.45 | 04/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919978 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,200.00 | 04/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) | No dispute reported | 06/30/2026 | 1244046684 |
| Principal investigator 1 | ModernaTX, Inc. | $14,934.87 | 04/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955525 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,400.00 | 04/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046680 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 04/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955385 |
| Principal investigator 1 | ModernaTX, Inc. | $11,600.00 | 04/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955483 |
| Principal investigator 1 | ModernaTX, Inc. | $9,000.00 | 04/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955523 |
| Principal investigator 1 | ModernaTX, Inc. | $2,057.17 | 04/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955493 |
| Principal investigator 1 | ModernaTX, Inc. | $500.86 | 04/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955531 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,960.00 | 04/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) | No dispute reported | 06/30/2026 | 1244046686 |
| Principal investigator 1 | ModernaTX, Inc. | $1,869.00 | 04/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | No dispute reported | 06/30/2026 | 1252955405 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 04/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | No dispute reported | 06/30/2026 | 1202474374 |
| Principal investigator 1 | Genentech, Inc. | $10,080.00 | 04/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211682094 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,178.10 | 04/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130267 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,525.50 | 04/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130303 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,660.00 | 03/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185550705 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 03/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130920 |
| Principal investigator 1 | Novavax Inc | $14,022.10 | 03/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919120 |
| Principal investigator 1 | Eli Lilly and Company | $43,608.29 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORFORGLIPRON ONCE DAILY ORAL VERSUS PLACEBO IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES - A RANDOMIZED, DOUBLE-BLIND TRIAL (ADVANCE-ATTAIN-ADOLESCENTS) | No dispute reported | 06/30/2026 | 1187892652 |
| Principal investigator 1 | ModernaTX, Inc. | $777.09 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955399 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955491 |
| Principal investigator 1 | ModernaTX, Inc. | $1,300.00 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955535 |
| Principal investigator 1 | ModernaTX, Inc. | $13,281.00 | 03/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | No dispute reported | 06/30/2026 | 1252955539 |
| Principal investigator 1 | ModernaTX, Inc. | $5,994.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955497 |
| Principal investigator 1 | ModernaTX, Inc. | $1,520.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003495 |
| Principal investigator 1 | ModernaTX, Inc. | $1,336.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003505 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,750.00 | 03/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192133311 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 03/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192133328 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $25,688.10 | 03/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130263 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,750.00 | 03/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130903 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 03/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130913 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 03/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130926 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,267.00 | 03/14/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226091274 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $650.00 | 03/14/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226091290 |
| Principal investigator 1 | ModernaTX, Inc. | $4,590.00 | 03/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | No dispute reported | 06/30/2026 | 1252955447 |
| Principal investigator 1 | ModernaTX, Inc. | $1,300.00 | 03/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | No dispute reported | 06/30/2026 | 1252955537 |
| Principal investigator 1 | ModernaTX, Inc. | $330.75 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955411 |
| Principal investigator 1 | ModernaTX, Inc. | $303.75 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955461 |
| Principal investigator 1 | ModernaTX, Inc. | $429.30 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955501 |
| Principal investigator 1 | ModernaTX, Inc. | $810.00 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955503 |
| Principal investigator 1 | ModernaTX, Inc. | $945.00 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955543 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,683.50 | 03/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717199 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,426.00 | 03/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) | No dispute reported | 06/30/2026 | 1244046688 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $35,167.64 | 03/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717472 |
| Principal investigator 1 | ModernaTX, Inc. | $663.00 | 03/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955563 |
| Principal investigator 1 | PFIZER INC. | $12,759.60 | 03/05/2025 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228783298 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,800.00 | 03/04/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | No dispute reported | 06/30/2026 | 1226130295 |
| Principal investigator 1 | ModernaTX, Inc. | $104.00 | 02/28/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955387 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $300.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554961 |
| Principal investigator 1 | ModernaTX, Inc. | $1,525.15 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955475 |
| Principal investigator 1 | ModernaTX, Inc. | $513.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955511 |
| Principal investigator 1 | ModernaTX, Inc. | $3,006.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003493 |
| Principal investigator 1 | ModernaTX, Inc. | $4,560.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003507 |
| Principal investigator 1 | ModernaTX, Inc. | $5,225.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003525 |
| Principal investigator 1 | Novavax Inc | $28,170.06 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242919111 |
| Principal investigator 1 | ModernaTX, Inc. | $280.00 | 02/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955455 |
| Principal investigator 1 | ModernaTX, Inc. | $2,706.21 | 02/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,696.00 | 02/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130207 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046692 |
| Principal investigator 1 | ModernaTX, Inc. | $19,168.50 | 02/21/2025 | Non-covered Recipient Entity MEDPHARMICS LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252955407 |
| Principal investigator 1 | ModernaTX, Inc. | $280.00 | 02/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955463 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 02/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955541 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 02/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955547 |
| Principal investigator 1 | ModernaTX, Inc. | $83.20 | 02/18/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252955389 |
| Principal investigator 1 | ModernaTX, Inc. | $472.50 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955421 |
| Principal investigator 1 | ModernaTX, Inc. | $93.96 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955425 |
| Principal investigator 1 | ModernaTX, Inc. | $182.25 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955467 |
| Principal investigator 1 | ModernaTX, Inc. | $122.85 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955469 |
| Principal investigator 1 | ModernaTX, Inc. | $148.50 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955473 |
| Principal investigator 1 | ModernaTX, Inc. | $137.70 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955477 |
| Principal investigator 1 | ModernaTX, Inc. | $13.50 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955479 |
| Principal investigator 1 | ModernaTX, Inc. | $202.50 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955507 |
| Principal investigator 1 | ModernaTX, Inc. | $270.00 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955509 |
| Principal investigator 1 | ModernaTX, Inc. | $384.75 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955515 |
| Principal investigator 1 | ModernaTX, Inc. | $749.25 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955551 |
| Principal investigator 1 | ModernaTX, Inc. | $114.75 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955553 |
| Principal investigator 1 | ModernaTX, Inc. | $43.20 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955557 |
| Principal investigator 1 | ModernaTX, Inc. | $336.15 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955561 |
| Principal investigator 1 | ModernaTX, Inc. | $469.80 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | No dispute reported | 06/30/2026 | 1252955565 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 02/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO | No dispute reported | 06/30/2026 | 1192130945 |
| Principal investigator 1 | ModernaTX, Inc. | $350.00 | 02/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955415 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 02/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252955499 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $409.20 | 02/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046690 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,100.00 | 01/30/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717299 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,843.78 | 01/30/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717315 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $65,366.95 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185550707 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,274.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185550717 |
| Principal investigator 1 | ModernaTX, Inc. | $2,750.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955395 |
| Principal investigator 1 | ModernaTX, Inc. | $105.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955397 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955401 |
| Principal investigator 1 | ModernaTX, Inc. | $850.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955441 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955443 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | No dispute reported | 06/30/2026 | 1252955445 |
| Principal investigator 1 | ModernaTX, Inc. | $3,040.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003499 |
| Principal investigator 1 | ModernaTX, Inc. | $12,540.00 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003501 |
| Principal investigator 1 | ModernaTX, Inc. | $5,678.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253003521 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 01/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955435 |
| Principal investigator 1 | Novavax Inc | $98,774.52 | 01/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age | No dispute reported | 06/30/2026 | 1242921645 |
| Principal investigator 1 | AstraZeneca UK Limited | $7,620.00 | 01/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185550711 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $46,177.60 | 01/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1192133303 |
| Principal investigator 1 | ModernaTX, Inc. | $39,621.65 | 01/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | No dispute reported | 06/30/2026 | 1252955403 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,556.75 | 01/21/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226130175 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 01/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955439 |
| Principal investigator 1 | ModernaTX, Inc. | $11,190.00 | 01/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252955527 |
| Principal investigator 1 | AstraZeneca UK Limited | $16,122.75 | 01/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika | No dispute reported | 06/30/2026 | 1185550701 |